Tenofovir disoproxil fumarate

Drug Profile

Tenofovir disoproxil fumarate

Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; HIV infections

Most Recent Events

  • 20 Feb 2017 Blueclinical initiates enrolment in a phase II trial for HIV infections (Combination therapy) in Portugal (EudraCT2016-000346-61)
  • 01 Dec 2016 GlaxoSmithKline completes a phase III trial in Hepatitis B in China (NCT01300234)
  • 11 Nov 2016 Efficacy and adverse events data from a phase III trial in Hepatitis B presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top